Lilly wraps up Sigilon Therapeutics acquisition to amplify Type 1 diabetes research
Eli Lilly and Company (Lilly) has formally announced the culmination of its $309.6 million takeover of biopharma trailblazer, Sigilon Therapeutics, Inc. (NASDAQ: SGTX). This strategic ... Read More
What is Crohn’s disease – symptoms and causes
What is Crohn's disease? How common is Crohn's disease? Crohn's disease is a form of inflammatory bowel disease (IBD). Crohn's disease typically occurs within the ... Read More